vTv Therapeutics (NASDAQ:VTVT) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 target price for the company.

vTv Therapeutics Price Performance

Shares of vTv Therapeutics stock opened at $15.02 on Tuesday. The business has a fifty day simple moving average of $16.45 and a two-hundred day simple moving average of $15.35. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $30.99. The company has a market capitalization of $47.91 million, a price-to-earnings ratio of -3.32 and a beta of 1.07.

Institutional Investors Weigh In On vTv Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VTVT. JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $25,000. Geode Capital Management LLC lifted its holdings in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,327 shares in the last quarter. Finally, FMR LLC acquired a new stake in shares of vTv Therapeutics during the third quarter worth $2,402,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.